Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice

Clinical and Vaccine Immunology

Volumn 17, Issue 3, 2010, Pages 317-324

  Mielcarek, Nathalie ^a,b,c   Debrie, Anne Sophie ^a,b,c   Mahieux, Severine ^a,b,c   Locht, Camille ^a,b,c  

^a INSTITUT PASTEUR DE LILLE   (France)

^b INSERM U1019   (France)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; GAMMA INTERFERON; PERTUSSIS VACCINE; TETRAVAC; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; LUNG; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROTECTION; SPLEEN CELL;

EID: 77649249575     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00322-09     Document Type: Article

References (33)

1. Antoine, R., and C. Locht. 1990. Roles of the disulfide bond and the carboxyterminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect. Immun. 58:1518-1526.
2. Belloni, C., A. DeSilvestri, C. Tinelli, M. A. Avanzini, M. Marconi, F. Strano, G. Rondini, and G. Chirico. 2003. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 111:1042-1045.
3. Bouchez, V., V. Caro, E. Levillain, G. Guigon, and N. Guiso. 2008. Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS One 3:e2437.
4. Crowcroft, N. S., C. Stein, P. Duclos, and M. Birmingham. 2003. How best to estimate the global burden of pertussis? Lancet Infect. Dis. 3:413-418.
5. de Jong, M. F. 1987. Prevention of atrophic rhinitis in piglets by means of intranasal administration of a live non-AR-pathogenic Bordetella bronchiseptica vaccine. Vet. Q. 9:123-133.
6. Edwards, K. M., and M. D. Dekker. 1996. Acellular pertussis vaccines for infants. N. Engl. J. Med. 334:391-392.
7. Forsyth, K., T. Tan, C. H. von König, J. J. Caro, and S. Plotkin. 2005. Potential strategies to reduce the burden of pertussis. Pediatr. Infect. Dis. J. 24:S69-S74.
8. Guiso, N., C. Capiau, G. Carletti, J. Poolman, and P. Hauser. 1999. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 17:2366-2376.
9. He, Q., and J. Mertsola. 2008. Factors contributing to pertussis resurgence. Future Microbiol. 3:329-339.
10. Heikkinen, E., T. Kallonen, L. Saarinen, R. Sara, A. J. King, F. R. Mooi, J. T. Soini, J. Mertsola, and Q. He. 2007. Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One 2:e904.
11. Heininger, U. 2001. Pertussis: an old disease that is still with us. Curr. Opin. Infect. Dis. 14:329-335.
12. Hellwig, S. M., A. B. van Spriel, J. F. Schellekens, F. R. Mooi, and J. G. van de Winkel. 2001. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect. Immun. 69:4846-4850.
13. Hewlett, E. L., and K. M. Edwards. 2005. Clinical practice: pertussis - not just for kids. N. Engl. J. Med. 352:1215-1222.
14. Huang, C. C., P. M. Chen, J. K. Kuo, W. H. Chui, S. T. Lin, H. S. Lin, and Y. C. Lin. 1962. Experimental whooping cough. N. Engl. J. Med. 266:105-111.
15. Jackson, L. A., B. A. Carste, D. Malais, and J. Froeschle. 2002. Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr. Infect. Dis. J. 21:781-786.
16. Kendrick, P. L., G. Eldering, M. K. Dixon, and J. Misner. 1947. Mouse protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route for challenge. Am. J. Public Health 37:803-810.
17. Locht, C., M. C. Geoffroy, and G. Renauld. 1992. Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbrae share sequence similarities with the papC and papD gene families. EMBO J. 11:3175-3183.
18. Mascart, F., V. Verscheure, A. Malfroot, M. Hainaut, D. Pierard, S. Temerman, A. Peltier, A.-S. Debrie, J. Levy, G. Del Giudice, and C. Locht. 2003. Bordetella pertussis infection in 2-months-old infants promotes type I T cell responses. J. Immunol. 170:1504-1509.
19. Menozzi, F. D., C. Gantiez, and C. Locht. 1991. Interaction of the Bordetella pertussis filamentous haemagglutinin with heparin. FEMS Microbiol. Lett. 62:59-64.
20. Menozzi, F. D., R. Mutombo, G. Renauld, C. Gantiez, J. H. Hannah, E. Leininger, M. J. Brennan, and C. Locht. 1994. Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. Infect. Immun. 62:769-778.
21. Mielcarek, N., J. Cornette, A. M. Schacht, R. J. Pierce, C. Locht, A. Capron, and G. Riveau. 1997. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. Infect. Immun. 65:544-550.
22. Mielcarek, N., A. S. Debrie, D. Raze, J. Bertout, C. Rouanet, A. Ben Younes, C. Creuzi, J. Engle, W. E. Goldman, and C. Locht. 2006. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping-cough. PLoS Pathog. 2:662-670.
23. Mills, K. H. G. 2001. Immunity to Bordetella pertussis. Microbes Infect. 3:3331-3346.
24. Mills, K. H., M. Brady, E. Ryan, and B. P. Mahon. 1998. A respiratory challenge model for infection with Bordetella pertussis: application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity. Dev. Biol. Stand. 95:31-41.
25. Mooi, F. R., and S. C. De Greeff. 2007. The case for maternal vaccination against pertussis. Lancet Infect. Dis. 7:614-624.
26. Mooi, F. R., I. H. M. van Loo, M. van Gent, Q. He, M. J. Bart, C. J. Heuvelman, S. C. de Greeff, D. Diavatopoulos, P. Teunis, N. Nagelkerke, and J. Mertsola. 2009. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg. Infect. Dis. 15:1206-1213.
27. Roberts, M., D. Maskell, P. Novotny, and G. Dougan. 1990. Construction and characterization in vivo of Bordetella pertussis aroA mutants. Infect. Immun. 58:732-739.
28. Roduit, C., P. Bozzotti, N. Mielcarek, P. H. Lambert, G. del Giudice, C. Locht, and C. A. Siegrist. 2002. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect. Immun. 70:3521-3528.
29. Sekura, R. D., F. Fish, C. R. Manclark, B. Meade, and Y. L. Zhang. 1983. Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J. Biol. Chem. 258:14647-14651.
30. Shade, F. J., and R. A. Goodnow. 1979. Intranasal immunization of dogs against Bordetella bronchiseptica-induced tracheobronchitis (kennel cough) with modified live-Bordetella bronchiseptica vaccine. Am. J. Vet. Res. 40:1241-1243.
31. Siegrist, C. A. 2001. Neonatal and early life vaccinology. Vaccine 19:3331-3346.
32. Storsaeter, J., J. Wolter, and C. Locht. 2007. Pertussis vaccines, p. 245-288. In C. Locht (ed.), Bordetella molecular microbiology. Horizon Bioscience, Norfolk, United Kingdom.
33. Wirsing von König, C. H., S. Halperin, M. Riffelmann, and N. Guiso. 2002. Pertussis of adults and infants. Lancet Infect. Dis. 2:744-750.